Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis MeetingBusiness Wire • 09/07/21
Alnylam (ALNY) Up 7.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/02/21
Alnylam Pharmaceuticals Flying High Despite Limited Near-Term Clinical CatalystsSeeking Alpha • 08/10/21
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with CardiomyopathyBusiness Wire • 08/09/21
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/03/21
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/03/21
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period ActivityBusiness Wire • 08/03/21
Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic TissuesBusiness Wire • 07/29/21
Alnylam's Lumasiran Substantially Reduces Plasma Oxalate Levels PH1 Patients With Severe Renal ImpairmentBenzinga • 07/29/21
Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1Business Wire • 07/29/21
Analysts Estimate Alnylam Pharmaceuticals (ALNY) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/27/21
Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial ResultsBusiness Wire • 07/21/21
Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate HypertensionBusiness Wire • 06/30/21
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR AmyloidosisBusiness Wire • 06/24/21
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society's 2021 Annual MeetingBusiness Wire • 06/07/21